Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 50 of 231 for:    CALCITONIN SALMON

Phase II Two-step Radioimmunotherapy Clinical Study in Medullary Thyroid Carcinoma (RIT in MTC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00467506
Recruitment Status : Completed
First Posted : April 30, 2007
Last Update Posted : November 11, 2011
Sponsor:
Information provided by:
Nantes University Hospital

Brief Summary:
Phase II clinical trial assessing efficacy and toxicity of pretargeted radioimmunotherapy using anti-CEAxanti-DTPA bispecific antibody and di-DTPA-131I peptide in patients with reccurrence of medullary thyroid carcinoma (abnormal calcitonin level and biomarkers doubling time lower than 5 years)

Condition or disease Intervention/treatment Phase
Thyroid Neoplasms Drug: bispecific antibody and di-DTPA-131I Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Allocation: Non-Randomized
Intervention Model: Factorial Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Two-step Radioimmunotherapy Clinical Study in Medullary Thyroid Carcinoma
Study Start Date : May 2004
Actual Primary Completion Date : January 2011
Actual Study Completion Date : January 2011

Resource links provided by the National Library of Medicine

Drug Information available for: Thyroid





Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 18 -75 years
  • Karnofsky ≥ 70%
  • Histological diagnosis of medullary thyroid carcinoma
  • Calcitonin serum level Ê 100 pg/ml and Calcitonin or CEA doubling time £ 5 years
  • Normal liver and renal functions
  • Granulocytes ≥ 1500/mm3 and platelets ≥ 150 000/mm3
  • No immunization
  • Consent form signed

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00467506


Locations
Layout table for location information
France
Centre François Baclesse
Caen, France, 14076
CHU de Grenoble
Grenoble, France, 38043
hôpital du Cluzeau
Limoges, France, 87042
CHU
Lyon, France, 69394
Hôpital de la timone
Marseille, France, 13385
CHU
Nantes, France, 44093
CHU
Rouen, France, 76230
Centre René Huguenin
Saint Cloud, France, 92210
Centre René Gauducheau
Saint Herblain, France, 440805
Centre Paul Strauss
Strasbourg, France, 67065
Centre Claudius Régaud
Toulouse, France, 31052
Sponsors and Collaborators
Nantes University Hospital
Investigators
Layout table for investigator information
Principal Investigator: Francoise Bodere, MD CHU de Nantes

Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00467506     History of Changes
Other Study ID Numbers: BRD 03/2-U
First Posted: April 30, 2007    Key Record Dates
Last Update Posted: November 11, 2011
Last Verified: November 2011
Keywords provided by Nantes University Hospital:
Recurrence of medullary thyroid carcinoma: abnormal calcitonin level and biomarkers doubling time lower than 5 years after initial surgery
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Thyroid Neoplasms
Thyroid Diseases
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Endocrine System Diseases
Endocrine Gland Neoplasms
Neoplasms by Site
Head and Neck Neoplasms
Antibodies
Antibodies, Bispecific
Immunologic Factors
Physiological Effects of Drugs